Sreekanth Chandrupatla, MD
Gastroenterology · Crystal River, FLNPI 1881623767
Payments from drug & device makers
Across 308 payments — averaging $30.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Endogastric Solutions, Inc$2K
- Johnson & Johnson$860
- Medtronic$339
- Bristol Myers Squibb$318
- Boston Scientific$296
- plus $4K from 30 others
What the payments were for
- Consulting fees$220%
- Travel & lodging$1,48616%
- Food & beverage$7,98984%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 115 | $2,423 |
| Endogastric Solutions, Inc | 5 | $1,759 |
| Johnson & Johnson | 22 | $860 |
| Medtronic | 5 | $339 |
| Bristol Myers Squibb | 18 | $318 |
| Boston Scientific | 4 | $296 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 16 | $268 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $267 |
| Intercept Pharmaceuticals, Inc. | 9 | $252 |
| Ipsen Biopharmaceuticals, Inc | 6 | $251 |
| Sanofi | 6 | $246 |
| Madrigal Pharmaceuticals | 5 | $243 |
| Phathom Pharmaceuticals, Inc. | 24 | $226 |
| Lilly USA, LLC | 5 | $220 |
| E.r. Squibb & Sons, L.L.C. | 3 | $184 |
| Nestle Healthcare Nutrition Inc. | 12 | $182 |
| Pfizer | 9 | $156 |
| Ferring Pharmaceuticals Inc. | 4 | $148 |
| Gilead | 7 | $142 |
| Janssen Scientific Affairs, LLC | 1 | $120 |
| Edwards Lifesciences | 1 | $73 |
| Fujifilm Healthcare Americas Corporation | 1 | $71 |
| Enterra Medical, Inc. | 3 | $71 |
| Smith+Nephew | 1 | $63 |
| Vivus LLC | 3 | $52 |
| UCB, Inc. | 3 | $43 |
| Lucid Diagnostics Inc. | 2 | $37 |
| Novo Nordisk | 1 | $32 |
| Regeneron Healthcare Solutions, Inc. | 1 | $28 |
| Ardelyx, Inc. | 1 | $24 |
| Amgen | 1 | $20 |
| Exact Sciences | 1 | $20 |
| Boehringer Ingelheim | 1 | $20 |
| Evoke Pharma, Inc. | 1 | $15 |
| Merck | 1 | $13 |
| Shionogi Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,496 in reported general payments places this provider in the 70th percentile of 1,388 gastroenterology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 43 | $265,112 |
| OcalivaObeticholic Acid | 14 | $134,798 |
| ZenpepLipase/Protease/Amylase | 12 | $126,257 |
| XifaxanRifaximin | 29 | $83,052 |
| Humira(Cf) PenAdalimumab | 12 | $76,589 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 311 | $53,298 |
| LinzessLinaclotide | 47 | $49,144 |
| Mesalamine | 31 | $30,661 |
| Omeprazole | 675 | $9,128 |
| Ursodiol | 11 | $4,722 |
| Colestipol Hcl | 70 | $4,669 |
| Pantoprazole Sodium | 221 | $3,749 |
| Lubiprostone | 27 | $2,771 |
| Sucralfate | 54 | $1,849 |
| Ondansetron OdtOndansetron | 49 | $1,744 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess | $2,423 | $314,25590 claims |
| Intercept Pharmaceuticals, Inc.Ocaliva | $252 | $134,79814 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $268 | $83,05229 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $148 | $53,298311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,388 gastroenterology providers in Florida.
Other gastroenterology in Crystal River
- Paul HellsternCrystal River$4.5M
- Siddharth MathurCrystal River$966K
- Howard SchwartzTavernier$38.8M
- Guy NeffSarasota$17.6M
- Syed LateefClermont$6.4M
- Jeffrey SchneiderCoral Springs$6M
- Zaid RanaMiami$5.4M
- David NelsonGainesville$5.2M
- Alan WeintraubTampa$4.7M
- Curtis FreedlandNew Port Richey$4.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.